MW02
/ Mabwell (Shanghai) Biosci
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 28, 2022
A Study to Evaluate the Efficacy and Safety of MW02 in the Treatment of nAMD
(clinicaltrials.gov)
- P2/3 | N=433 | Recruiting | Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.
New P2/3 trial • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration
1 to 1
Of
1
Go to page
1